The Ridgewood Blog Brings a Free Market Laissez-faire Point of View to Local, New Jersey State and National Issues.
The Covid-19 pandemic has affected everyone around the world since its arrival in 2020. Most of us have been affected by Covid-19, whether it be knowing someone who has experienced it or known people who have lost a loved one because of it. At present, it shows no sign of abating.
Continue reading 6 Good Reasons That Will Convince You To Get A Covid-19 Vaccine As Soon As Possible
the staff of the Ridgewood blog
Ridgewood NJ, Any resident who wishes to obtain a COVID-19 vaccine must register on the State of NJ site, which is: covid19.nj.gov/vaccine. Once registered, an email will let you know if you are eligible at the present time or if you will have to wait for a future date, based on the current guidelines (the current guidelines are attached to this email). If you are eligible for a vaccine at this time, a list of sites where the vaccine is being given will be provided. Choose the location where you wish to go, and register for that site. Continue reading Any resident who wishes to obtain a COVID-19 vaccine must register on the State of NJ site
the staff of the Ridgewood blog
London UK, AstraZeneca’s COVID-19 vaccine has been approved for emergency supply in the UK, with the first doses being released today so that vaccinations may begin early in the New Year. The approval was hailed by Prime Minister Boris Johnson as “a triumph for British science.”
The shot is expected to be rolled out next week and would be added to the Pfizer-BioNTech vaccine which has so far been given to 600,000 people in the U.K., according to government statistics.
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has provided authorisation for emergency supply of COVID-19 Vaccine AstraZeneca, formerly AZD1222, for the active immunisation of individuals 18 years or older. The authorisation recommends two doses administered with an interval of between four and 12 weeks. This regimen was shown in clinical trials to be safe and effective at preventing symptomatic COVID-19, with no severe cases and no hospitalisations more than 14 days after the second dose.
Continue reading AstraZeneca’s COVID-19 vaccine Gets Emergency Approval in the UK
photos courtesy of Valley Hospital
the staff of the Ridgewood blog
Ridgewood NJ, Valley’s first shipment of the Pfizer #COVID19 vaccine arrived late Thursday afternoon. Valley in now able to be able to begin to vaccinate our doctors, nurses, and other staff who continue to battle on the frontlines of the pandemic. Valley Hospital is offering the vaccine in accordance with guidance from state and federal health officials for the fast and equitable distribution of the vaccine. In time, Valley and all healthcare providers expect to receive supplies large enough to begin vaccinating the public, and we will communicate those details to you when that day is in sight.
Continue reading Valley Hospital Receives First Doses of COVID-19 Vaccine
the staff of the Ridgewood blog
CAMBRIDGE, Mass. Moderna, Inc., (Nasdaq:MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today confirmed that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) recommended that the FDA grant an Emergency Use Authorization (EUA) for the Company’s COVID-19 vaccine candidate, mRNA-1273. 20 VRBPAC members recommended for EUA, 0 members voted against, and 1 abstained.
the staff of the Ridgewood blog
Trenton NJ, In preparation for the arrival of COVID-19 vaccines to New Jersey, Governor Phil Murphy signed Executive Order No. 207, which automatically enrolls residents who choose to receive a COVID-19 vaccine into the state’s existing vaccine registry. The Governor’s Executive Order changes inclusion into the New Jersey Immunization Information System from an opt-in to an opt-out program for residents who elect to receive a COVID-19 vaccine. That group of residents will be automatically enrolled into the system, and will then be permitted to opt-out of the registry 30 days after the public health emergency expires. Currently, all individuals born on or after January 1, 1998 are automatically enrolled in the registry, unless they opt-out of the registry. Any individual born prior to January 1, 1998 can elect to opt-in to the registry.
the staff of the Ridgewood blog
CAMBRIDGE Mass , Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that the primary efficacy analysis of the Phase 3 study of mRNA-1273 conducted on 196 cases confirms the high efficacy observed at the first interim analysis. The data analysis indicates a vaccine efficacy of 94.1%. Safety data continue to accrue and the study continues to be monitored by an independent, NIH-appointed Data Safety Monitoring Board (DSMB). The Company also announced that today, Moderna plans to request an Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) and conditional approval from the European Medicines Agency (EMA). The Phase 3 study, known as the COVE study, enrolled more than 30,000 participants in the U.S. and is being conducted in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), and the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services.
the satff of the Ridgewood blog
New Brunswick NJ, while polling has produced less than stellar results in the last 20 years , so take this with a grain of salt , according a recent Rutgers-Eagleton Poll between 36 percent and 47 percent of New Jerseyans say they will “probably” or “definitely” not get vaccinated against COVID-19, with response rates varying depending on how the question is asked, according to the latest Rutgers-Eagleton Poll.
the staff of the Ridgewood blog
New York NJ, The first U.S. patients have been dosed in a clinical trial testing whether four experimental messenger RNA (mRNA) vaccine candidates can prevent infection with the virus that causes 2019 coronavirus disease (COVID-19).
Continue reading U.S. Clinical Trial for COVID-19 Vaccine Starts at NYU Langone Health
the staff of the Ridgewood blog
